-
Product Insights
Colorectal Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Colorectal Tumor - Drugs In Development, 2023’, provides an overview of the Colorectal Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colorectal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Macular Edema – Drugs In Development, 2023
Global Markets Direct’s, ‘Macular Edema - Drugs In Development, 2023’, provides an overview of the Macular Edema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Drugs In Development, 2022, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape. Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the...
-
Product Insights
Gastric Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gastric Cancer signs and symptoms include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Treatment includes surgery, chemotherapy, and radiation therapy. The Gastric Cancer pipeline drugs market research report provides an analysis of the Gastric Cancer drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and...
-
Sector Analysis
Gastric and Gastroesophageal Junction Adenocarcinoma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029
The Gastric and Gastroesophageal Junction Adenocarcinoma (G/GEJAC) market size across the 8MM was valued at $1.12 billion in 2019 and is forecast to grow at a CAGR of more than 15% during 2019-2029. Growth of the market will be driven by the recent expansions of Opdivo and Keytruda into the first-line metastatic setting, further expansions for multiple agents across the 8MM, and the launches of nine pipeline agents.
-
Track & Monitor
Pharmaceuticals Industry Deals and Trends in February 2019 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for February 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2019. The report portrays detailed comparative data on the number of deals and their value in the last...